Targeting RTN4/NoGo-Receptor reduces levels of ALS protein ataxin-2
Ontology highlight
ABSTRACT: Gene-based therapeutic strategies to lower ataxin-2 levels are emerging for neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia type 2 (SCA2). To identify additional ways of reducing ataxin-2 levels, we performed a genome-wide screen in human cells for regulators of ataxin-2 and identified RTN4R, the gene encoding the RTN4/NoGo-Receptor, as a top hit. This dataset contains the RNA-sequencing data used to support the conclusions from this study.
ORGANISM(S): Homo sapiens
PROVIDER: GSE200530 | GEO | 2022/10/18
REPOSITORIES: GEO
ACCESS DATA